Inmode Ltd

InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. It also designs, develops, manufactures and markets non-invasive medical aesthetic products that target a array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture and superficial benign vascular and pigmented lesions. The company was founded by Moshe Mizrahy and Michael Kreindel on January 2, 2008 and is headquartered in Yokneam, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InMode reports record revenue, plans global expansion for growth

InMode's strong financial performance in Q4 and full year 2022, driven by successful product launches and global expansion efforts, positions the company for continued growth. Despite challenges in pinpointing market penetration, opportunities lie in new product launches and untapped physician markets.

InMode reports robust Q1 earnings, eyes international expansion and talent

InMode delivered strong Q1 2023 results, driven by revenue growth, international expansion, and strategic hiring practices, positioning the company for continued success.
While facing challenges such as rising operating expenses and talent acquisition complexities, InMode's focus on quality, innovation, and financial strength presents opportunities for sustainable growth.
By leveraging opportunities in talent acquisition, product innovation, and international expansion, InMode can enhance market competitiveness and drive long-term value creation.
Overall, InMode's performance, strengths, and strategic outlook indicate a positive trajectory for future growth and profitability, supported by a solid financial foundation.

InMode achieves record Q2 earnings, eyes global expansion and innovation

InMode's strong financial performance, global expansion, and focus on innovation position it well for future growth. While facing challenges in managing increased expenses and scaling sales, the company's strategic investments and market positioning offer promising opportunities for expansion and market leadership.

InMode reports steady Q3 growth amidst challenges and opportunities

InMode's Q3 performance reflects resilience amid industry seasonality and macro challenges, with revenue growth and strong margins.
The company's focus on innovation, IP protection, and strategic acquisitions positions it for sustained leadership and growth.
Challenges in leasing processes and legal battles require proactive management, but opportunities in M&A and product growth remain.
Despite uncertainties for 2024, InMode's strategic initiatives and market presence offer a foundation for future success.

InMode reports record 2023 revenue, eyes international expansion and M&A

InMode navigated industry challenges in 2023 with resilience, focusing on innovation, global expansion, and cost management. Despite facing headwinds, the company remains optimistic about growth opportunities, leveraging its strong financial position and strategic initiatives for future success.

InMode reports Q1 revenue of $80.3M, adjusts guidance for 2024

InMode faces challenges from industry headwinds and manufacturing delays but shows strength in new platform launches and North America performance.
Opportunities lie in strategic initiatives, market demand confidence, and growth potential from new platforms.
Guidance adjustments reflect proactive measures to navigate uncertainties and drive future growth.
Overall, InMode remains resilient amidst challenges, poised for growth with strategic focus areas.

InMode reports Q2 revenue of $86.4 million, adjusts 2024 guidance

InMode faces challenges with declining demand for treatments and international sales, but is leveraging new platform launches and cost management to drive performance. The company is adapting to market conditions and geopolitical issues to capitalize on growth opportunities.

InMode reports Q3 revenue of $130.2M, revises guidance amid challenges

InMode faced challenges from macroeconomic headwinds, impacting international sales and necessitating a revision of full-year guidance.
Despite these challenges, the company demonstrated strong operational performance with high gross margins and strategic management changes.
Opportunities lie in new platform adoption, market realignment, and leveraging the strong cash position for future growth.
Overall, InMode remains well-positioned to navigate challenges and capitalize on opportunities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This growth company's products are disruptive and its profits are burgeoning.

Got $3,000? Buy This 1 Healthcare Growth Stock Now

Intuitive Surgical

Both medical device makers are picking up steam with every passing quarter.

Better Buy: Intuitive Surgical or InMode?

InMode has generated much buzz and gains for shareholders and some have compared it to the incredibly successful Intuitive Surgical. The companies have many similarities and several differences.

InMode With Intuitive Surgical Potential? Let's Run The Numbers

Atlassian

We're coming into a historically strong month for the stock market, and these two names have been crushing it for investors. The post Why These Two Tech Stocks Are Outperforming the Stock Market appeared first on InvestorPlace.

Why These Two Tech Stocks Are Outperforming the Stock Market

YOKNEAM, Israel, Nov. 4, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will participate in the following upcoming virtual investor conferences:   Stifel 2021 Healthcare Conference Presentation is scheduled on Tuesday, November 16 at 9:20pm EST.

InMode to Participate in Upcoming Virtual Investor Conferences in November

Alkermes

BioNTech SE

Bruker

Heska

Joint

Prothena

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared first on InvestorPlace.

7 A-Rated Healthcare Stocks to Buy for the Long Haul

InMode Ltd. (INMD) CEO Moshe Mizrahy on Q3 2021 Results - Earnings Call Transcript

YOKNEAM, Israel, Oct. 26, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2021.

InMode Reports Record Third Quarter 2021 Financial Results: Quarterly Revenue of $94.2M, 58% Year-Over-Year Growth; GAAP Net Income of $44.7M, 87% increase compared to Q3 2020

INMD stock looks like one of the market's best, with incredible growth before, during, and after the novel coronavirus pandemic. But valuation has changed dramatically so far in 2021, and investors need to keep in mind the history of the medical aesthetics space.

Is InMode A Buy Or Sell After Recent Stock Split? Either Way, Be Careful Here

On Wednesday, InMode Ltd (NASDAQ:INMD) shares spiked more than 12%, extending Tuesday's gains. As a result, the stock is now up more than 21% this week after announcing better-than-expected preliminary Q3 results.

Is InMode stock a buy as shares spike 12% after solid preliminary Q3 results?

The stock price of Inmode Ltd (NASDAQ: INMD) increased by over 9% during intraday trading today. This is why it happened.

INMD Stock: Why It Increased Today

ESS Tech

Lithium Americas Corp

Nutriband

Ocugen, Inc.

Progenity

Quanterix

R.R. Donnelley & Sons

Tata Motors

Penny stocks are on the move Tuesday and we're taking a look at what's hot among traders of the volatile investments today. The post Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers appeared first on InvestorPlace.

Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers

YOKNEAM, Israel, Oct. 12, 2021 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2021 before the Nasdaq market opens on Tuesday, October 26, 2021.

InMode Expects Record Third Quarter 2021 Revenue of $93.5M-$94M, Raising Full-Year 2021 Revenue Guidance to $343M-$347M

InMode Ltd. (Nasdaq: INMD) recently announced a two-for-one (2:1) share split of its ordinary shares.

INMD Stock: 2-For-1 Split Goes Into Effect

Five-year average YoY revenue growth of 72.50%, EBITDA growth of 338.00%, and EPS growth of 653.94% are jaw-dropping. Profitability metrics (EBIT margin at 44.16% and Net Income margin at 44.34%) are impressive.

InMode: Wonderful Business With Deep Economic Moat

Traders might be mistaking more slices for a bigger pizza.

Why Shares of InMode Are Up 20% So Far This Week

Shares of Israeli medical technology company InMode Ltd. INMD, +5.34% jumped 2% premarket after the company announced plans for a 2-for-1 stock split.

InMode shares jump 2% premarket after company announces 2-for-1 stock split

YOKNEAM, Israel, Sept. 17, 2021 /PRNewswire/ -- InMode Ltd.

InMode Ltd. Announces 2-for-1 Share Split

Novavax

Sorrento Therapeutics Inc

Here are three healthcare stocks as nominees for a quick double in 2021.

3 COVID Stocks That Might Double Soon

InMode has consistently executed its business flawlessly with exceptional margins.

InMode: Taking Notes From Align Technologies

YOKNEAM, Israel, Sept. 9, 2021 /PRNewswire/ -- InMode Ltd.

InMode to Participate in Upcoming Virtual Conferences in September

IRVINE, Calif., Sept. 1, 2021 /PRNewswire/ -- InMode Ltd.

InMode Announces Launch of EvolveX Body Transforming Platform

InMode's treatments are intended for use in the field of aesthetic medicine, or medical science aimed at rendering the human body more beautiful.

InMode: Become More Beautiful Without Surgery

IRVINE, Calif., Aug. 17, 2021 /PRNewswire/ -- InMode Ltd.

InMode Announces Launch of EmpowerRF Women's Wellness Platform

YOKNEAM, Israel, Aug. 3, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that management will participate in the following upcoming conferences: Canaccord Genuity's 41st Annual Growth Virtual Conference Yair Malca, Chief Financial Officer, will participate in a virtual fireside chat on Thursday, August 12 at 11:30am ET, moderated by Kyle Rose, Managing Director, Medical Technology Analyst.

News for Inmode Ltd Stock (INMD)